Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidylinositol 3-kinase beta (PI3Kβ) is a class IA PI3K catalytic subunit, forming a heterodimer with regulatory subunits. It integrates signals from receptor tyrosine kinases (RTKs), G protein-coupled receptors (GPCRs), and small GTPases to regulate cell growth, proliferation, metabolism, and immune functions. PI3Kβ is implicated in cancer progression, making it a therapeutic target, but its inhibition can lead to immune-related side effects.
Inhibition of PI3Kβ kinase activity, blocking downstream signaling.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol 3-Kinase Beta Catalytic Subunit (PI3Kβ).